Share via Email


* Email To: (Separate multiple addresses with a semicolon)
* Your Name:
* Email From: (Your IP Address is 34.204.169.76)
* Email Subject: (personalize your subject)


Email Content:
Chick-News.com Poultry Industry News, Comments and more by Simon M. Shane

Hamlet Protein Evaluates AviStart®

07/28/2019

AviStart® is a proprietary enzyme-treated soy protein produced by Hamlet Protein A/S both in the EU and the U.S. The manufacturing process reduces trypsin inhibitor, oligosaccharides and antigens including beta-conglycinin compared to conventional solvent-extracted soybean meal. Assays for anti-nutritional factors in 180 samples of U.S. soybean meal showed a range of 1.4 to 5.5 mg/g dry matter for trypsin inhibitor, 4.3 to 8.3 percent stachyose and 0.6 to 1.9 percent raffinose with up to 8 percent oligosaccharides.

 

At the 2019 Poultry Science Association Meeting Hamlet Protein presented results of applied research demonstrating the value of including AviStart® in broiler diets*.  Assays showed that conventional soybean meal used in the study contained 2.2 mg/g of trypsin inhibitor and 9.3 percent oligosaccharides compared to AviStart® at 1.5 mg/g. Inclusion of 5 percent AviStart® in the basal diet reduced trypsin inhibitor by 7 percent and both beta-conglycin and oligosaccharides by 16 percent.

 

In the replicate pen trial, conducted by Southern Poultry Feed and Research, AviStart® was included in the starter diet for 14 days at a level of 5 percent.  The possible interaction of AviStart® with superimposition of Clostridium perfringens infection was evaluated together with including BMD in diets at 55 ppm throughout the growing period. The trial was designed to determine the effect of BMD alone and in combination with AviStart®.  The replicate pen trial comprised eight treatments each with eight pens of 25 male broilers vaccinated at day-old against coccidiosis.  For treatments challenged with C. perfringens, the pathogen was mixed in feed to attain a dose level of 1.0 x 108.5 CFU per chicken and fed during days 19 through 21.

 

At the termination of the 42-day trial, control broilers weighed 2.306 kg with a feed conversion of 1.790. Challenge with C. perfringens resulting in clinical necrotic enteritis (4.8 percent mortality) reduced body weight by 9.4 percent to 2.089 kg., significantly different from the control. Feed conversion was significantly elevated by 3.8 percent to 1.858 kg.  Inclusion of AviStart® at 5 percent in starter diets restored body weight numerically to 2.295 kg, with a feed conversion of 1.803, but these parameters were not statistically significantly different from respective controls.

 

Inclusion of BMD at 55 ppm did not significantly increase body weight over controls or the treatment receiving both BMD and AviStart® although feed conversion ratio was significantly lower compared to controls.  As expected, BMD was effective in reducing the impact of necrotic enteritis on weight gain and feed conversion.  With respect to the uninfected treatments, weight gain through 42 days was unaffected by inclusion of AviStart® or BMD or their combination.  In contrast AviStart® and BMD significantly decreased feed conversion ratio and their combination was significantly superior to treatments receiving either of the additives individually in diets. 

 

With respect to the treatment infected with Clostridium perfringens, AviStart® restored body weight to that of the uninfected controls as did BMD and the combination of BMD and AviStart®.  The major impact of including of AviStart® in diets through 14 days was to restore feed conversion ratio to that of the controls in the treatments challenged with Clostridium perfringens.

 

The trial demonstrated that AviStart® was equivalent to BMD both in addition cost and in improving weight gain and reducing the feed conversion ratio in broiler chicks through 42 days of growth.  AviStart® was equivalent to BMD in improving both commercial parameters of growth and feed conversion.

 

Based on the results of the trial, AviStart® would be expected to provide an approximately 7 to 1 benefit to cost ratio from flocks impacted by clinical necrotic enteritis, depending on cost of feed, severity of challenge and prevailing unit revenue. It is reasonable to anticipate a benefit to cost return ranging from 3 to 5 depending on financial and biological variables from inclusion of Avistart® in broiler feed for a post-placement of 14 days. Production benefits are attributed to removal of anti-nutritional factors inherent to enzymatic treatment during processing of soybean meal.

 

In commenting on the results of the sponsored trial Erik Visser CEO stated “Hamlet Protein has a long track record in manufacturing soy-based specialty proteins. Avistart® represents a new product for the poultry industry and is generating positive reports from field application”. Visser added “The introduction of Avistar® in Latin America, the E.U. and Asia is based on independent scientific research and is supported by specialized Hamlet Protein technical teams”

 

*Rasmussen, S. H. et al. Effect of an enzyme-treated soy protein on the performance of broiler chickens infected or uninfected with Clostridium perfringens. Proc. 2019 Poultry Science Association Meeting.


 
Copyright 2019 Simon M. Shane